Ur24Technology’s Active Extenal Catheter Is “Highly Effective” Emptying the Bladder, Comfortable and Easy to Use, Blinded Evaluation Shows

Study of 41 patients between ages 20 and 82 scored high on all five patient satisfaction metrics – including three perfect scores

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Prospective Blinded Evaluation of Ur24 Technology’s revolutionary active external catheter system found it to be “highly effective” at removing urine from the bladder without tissue injury while scoring high patient marks for comfort and ease of use.

The study involved 21 male and 20 female adult patients between the ages of 20 to 82 who used the TrueClr catheter system in both inpatient and outpatient settings over a one- to two-week period and included assessments of urinary collection, skin condition, comfort level, duration of use and ease of use.

The authors used National Pressure Injury Advisory Panel (NPIAP) pressure injury stages and verified skin monitoring assessments to evaluate each patient. The authors also used photo reviews of randomized, blinded examples of skin where TrueClr was applied, as well as two independent reviews of randomized photos and Registered Nurse skin assessments.

“The Ur24 TrueClr catheter was proven to be highly effective as an active external catheter capable of removing a significant amount of urine from the bladder without tissue injury,” the study results stated. Patient survey data collected in all five categories demonstrated “significant satisfaction” with TrueClr:

– 100% reported no skin irritation

– 100% agreed the catheter was intuitive to use

– 86% agreed it was comfortable to wear

– 70% strongly agreed and 30% agreed it was easy to use

– 100% would recommend TrueClr to other patients with similar clinical symptoms

Pierre Suarez, Vice President of Sales at Ur24Technology, said, “This study documents the effectiveness of the TrueClr catheter, showing strong results for patients – including three perfect scores in areas of patient satisfaction. TrueClr is designed to eliminate the estimated Five-Hundred Thousand or more Catheter Associated Urinary Tract Infections (CAUTIs) that occur annually in US acute care hospitals and nursing homes. These infections drive patient discomfort and health care costs and prolong patient lengths of stay. By removing the internal catheter, you remove the chance of a Catheter Associated Urinary Tract infection (CAUTI). The study’s recommendations conclude that “TrueClr has demonstrated it can successfully be used in a variety of clinical situations where either external catheters or indwelling catheters are currently used. We recommend considering the use of TrueClr in both the inpatient and outpatient settings where external or internal catheters are currently being used.”

The study authors are:

Christine Meliones, MSN, APRN, CPNP-AC/PC, FNP, CEPS, Advanced Care Provider Coordinator, Children’s Heart Institute, Children’s Memorial Herman Hospital, UT Health

Jon Meliones, MD, MS, FCCM, Professor of Pediatrics, Executive Co-Director Children’s Heart Institute, Division Chief of Cardiac Critical Care and Cardiology, Children’s Memorial Hermann Hospital, UT Health

Tyler Cutting, MBA, BSN-RN

US data shows that internal catheters are associated with 80% of hospital-related urinary tract infections, which cost the US health care system an estimated $6.2 Billion annually. Nearly 13,000 deaths annually are related to internal catheters.

Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the US and internationally, using its distribution network in 132 countries.

About Ur24Technology, Inc.

Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016. Five different external catheter prototypes were researched, designed and developed – leading to the TrueClr external catheter range of products. These revolutionary products perfectly fit the company’s core mission: to improve patient care through innovation.

Learn more at www.ur24technology.com or call 1-833-448-7248.

About DemeTECH Corp.

Headquartered in Miami, Florida, DemeTECH, is a world-renowned leader in surgical sutures, mesh and bone wax. DemeTECH strives to enhance doctor-patient relationships through hard work, dedication, and a commitment to the pursuance of cutting-edge technology and innovation. All DemeTECH’s products are made in the USA with American materials.

Learn more at https://demetech.us

Contacts

Victoria Suarez

Chief Operating Officer

949.629.5424

[email protected]
www.ur24technology.com

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.